Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance.

Authors:
Maltezou HC; Hatziantoniou S; Theodoridou K; Vasileiou K; Anastassopoulou C and 1 more

Journal:
Vaccine

Publication Year: 2023

DOI:
10.1016/j.vaccine.2023.02.067

PMCID:
PMC9968615

PMID:
36872145

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Vaccine

Abbreviation: Vaccine

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Long-term surveillance of invasive pneumococcal disease: The impact of 10-valent pneumococcal conju…
Reis JN; Azevedo J; de Oliveira AML and 11 more (2024) - Transparency Score: 3/6
Advances in intranasal vaccine delivery: A promising non-invasive route of immunization.
Kehagia E; Papakyriakopoulou P; Valsami G. (2023) - Transparency Score: 2/6
A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing …
Baek YJ; Kim WJ; Ko JH and 11 more (2023) - Transparency Score: 4/6
A humanized monoclonal antibody targeting protein a promotes opsonophagocytosis of Staphylococcus a…
Bernardino PN; Bhattacharya M; Chen X and 3 more (2023) - Transparency Score: 3/6
Antibody dependent disease enhancement (ADE) after COVID-19 vaccination and beta glucans as a safer…
Ikewaki N; Kurosawa G; Levy GA and 2 more (2023) - Transparency Score: 2/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."

Evidence found in paper:

"Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025